CAS 866460-33-5

Setipiprant

Descrizione:

Setipiprant è un composto chimico noto principalmente per il suo ruolo come antagonista selettivo del recettore della prostaglandina D2 2 (DP2), implicato in varie condizioni allergiche e infiammatorie. È classificato come una piccola molecola ed è stato studiato per le sue potenziali applicazioni terapeutiche nel trattamento di condizioni come asma e rinite allergica. La struttura molecolare di Setipiprant include un nucleo che consente il legame specifico al recettore DP2, inibendo così la sua attività. Questa azione può portare a una riduzione dell'infiammazione e di altri sintomi associati alle risposte allergiche. Setipiprant viene tipicamente somministrato per via orale e ha subito vari studi clinici per valutare la sua efficacia e il profilo di sicurezza. La sua farmacocinetica, che include assorbimento, distribuzione, metabolismo ed escrezione, è importante per comprendere il suo potenziale terapeutico e i regimi di dosaggio. In generale, Setipiprant rappresenta una via promettente nello sviluppo di terapie mirate per le malattie allergiche.

Formula: C₂₄H₁₉FN₂O₃

InChI: InChI=1S/C24H19FN2O3/c25-16-8-9-21-19(12-16)20-13-26(11-10-22(20)27(21)14-23(28)29)24(30)18-7-3-5-15-4-1-2-6-17(15)18/h1-9,12H,10-11,13-14H2,(H,28,29)

InChI key: InChIKey=IHAXLPDVOWLUOS-UHFFFAOYSA-N

SMILES: C(C(O)=O)N1C2=C(C=3C1=CC=C(F)C3)CN(C(=O)C=4C5=C(C=CC4)C=CC=C5)CC2

Sinonimi:

• ACT 129968
• 2-(2-(1-Naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid
• Setipiprant
• 8-Fluoro-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-5H-pyrido[4,3-b]indole-5-acetic acid
• 5H-Pyrido[4,3-b]indole-5-acetic acid, 8-fluoro-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-
• setipplant
• 2-(2-(1-naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid(Setipiprant,ACT129968)
• Setipiprant(ACT-129968, KYTH-105)
• 2-(2-(1-phthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid
• ACT129968;ACT-129968;ACT 129968
• 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid
• CS-2052
• Setipiprant(ACT-129968)
• RU58841 // Minoxidil // Setipiprant
• ACT 129968; ACT129968; KYTH-105; KYTH105; KYTH 105; SETIPIPRANT
• Seripiprant
• 2-[8-fluoro-2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl]acetic acid
• ACT129968
• CS-2512
• Setipirant

2-(2-(1-Naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid

CAS: 866460-33-5

Formula: C₂₄H₁₉FN₂O₃

Purezza: 98%

Colore e forma: Solid

Peso molecolare: 402.4177

Ref: IN-DA00GU6H

Setipiprant

CAS: 866460-33-5

Setipiprant

Purezza: ≥98%

Peso molecolare: 402.42g/mol

Ref: 54-BUP11176

Setipiprant

CAS: 866460-33-5

Setipiprant (ACT-129968) is an oral CRTH2 antagonist for asthma/allergy, targeting PGD2-induced inflammation (IC50: 6.0 nM).

Formula: C₂₄H₁₉FN₂O₃

Purezza: 99.16%

Colore e forma: Solid

Peso molecolare: 402.42

Ref: TM-T3520

Setipiprant(ACT-129968)

CAS: 866460-33-5

Setipiprant is a CRTH2-selective antagonist, which has been shown to be effective in reducing the incidence of asthma exacerbations and bronchoconstriction. It also has a good safety profile with no significant adverse effects observed in clinical studies. Setipiprant binds to the CRTH2 receptor and blocks its activation by prostaglandin D2 (PGD2) or leukotriene B4 (LTB4). This inhibition prevents the release of inflammatory mediators from mast cells, which are responsible for airway inflammation in asthma. Setipiprant is being developed as a potential treatment for chronic asthma, allergic rhinitis, and chronic obstructive pulmonary disease (COPD). The molecule has been shown to bind to the CRTH2 receptor with an affinity that is about 10 times higher than that of cetirizine, another anti-inflammatory drug. This binding profile makes setipiprant an ideal candidate for treatment of inflammatory diseases

Formula: C₂₄H₁₉FN₂O₃

Purezza: Min. 95%

Peso molecolare: 402.42 g/mol

Ref: 3D-RJB46033